These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 34652104)
21. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States. Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964 [No Abstract] [Full Text] [Related]
22. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA Tanner M Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349 [TBL] [Abstract][Full Text] [Related]
23. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. DeFronzo RA Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726 [TBL] [Abstract][Full Text] [Related]
24. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk. Bailey CJ Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565 [No Abstract] [Full Text] [Related]
25. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613 [TBL] [Abstract][Full Text] [Related]
26. Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications. Draznin B; Hirsch IB Am J Med; 2021 Apr; 134(4):420-422. PubMed ID: 33434557 [No Abstract] [Full Text] [Related]
30. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin. Meade LT; Mannka ML Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219 [No Abstract] [Full Text] [Related]
31. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918 [TBL] [Abstract][Full Text] [Related]
32. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. Chen Z; Li G Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606 [TBL] [Abstract][Full Text] [Related]
33. Glucose lowering and the kidney: are all drug classes equal? Wong MG; Jardine M; Perkovic V Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590 [No Abstract] [Full Text] [Related]
34. Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. Qiu M; Wei W; Wei XB; Liu SY Eur J Clin Pharmacol; 2022 Apr; 78(4):695-697. PubMed ID: 34860262 [No Abstract] [Full Text] [Related]
35. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation. Arnold MJ; Buelt A Am Fam Physician; 2022 Jun; 105(6):675-677. PubMed ID: 35704807 [No Abstract] [Full Text] [Related]
36. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment. Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806 [TBL] [Abstract][Full Text] [Related]
37. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?]. Ritz C; Jaafar J; Philippe J Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755 [TBL] [Abstract][Full Text] [Related]
38. GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice. Díaz-Trastoy O; Villar-Taibo R; Sifontes-Dubón M; Mozo-Peñalver H; Bernabeu-Morón I; Cabezas-Agrícola JM; Muñoz-Leira V; Peinó-García R; Martís-Sueiro A; García-López JM; Martínez-Olmos MA Clin Ther; 2020 Feb; 42(2):e1-e12. PubMed ID: 32005534 [TBL] [Abstract][Full Text] [Related]
40. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]